Analysis of the UPR and XBP1 in the treatment of hematological malignancies.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Abstract:
      The unfolded protein response (UPR) is a protective mechanism in cells enabling them to handle unfolded proteins which are not able to perform a specific and useful function in an organism. Numerous hematological malignancies take advantage of this protective feature, which makes the UPR a potential target to treat cancers like acute myeloid leukemia (AML) and multiple myeloma (MM). Certain drugs, such as IRE1α-RNase inhibitors and proteasome inhibitors (PI) may lead to apoptosis in cancerous cells by influencing XBP1, a key transcription factor of the UPR. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Die ungefaltete Proteinantwort (UPR) ist ein zellulärer Schutzmechanismus, der durch Ansammlung von Proteinen mit fehlerhafter Faltung ausgelöst wird. Zahlreiche hämatologische Malignome machen sich diese Schutzfunktion zunutze, was die UPR zu einem potenziellen Angriffsziel für die Behandlung von Krebserkrankungen – wie akuter myeloischer Leukämie (AML) und multiplem Myelom (MM) – macht. Bestimmte Medikamente wie IRE1α-RNase-Inhibitoren und Proteasom-Inhibitoren (PI) können durch die Modellierung eines wichtigen Transkriptionsfaktors der UPR, XBP1, zu der Apoptose von Krebszellen führen. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of MTA Dialog is the property of Deutscher Aerzte-Verlag GmbH and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)